Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense oligonucleotides targeting circPHAF1
- Development stage
- Preclinical
- Lead developer
- The First Affiliated Hospital of Guangzhou Medical University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Antisense oligonucleotides targeting circPHAF1 are synthetic oligonucleotides designed to inhibit the circular RNA circPHAF1. Developed by researchers at The First Affiliated Hospital of Guangzhou Medical University, these antisense oligonucleotides (ASOs) are being investigated for the treatment and prevention of calcium oxalate urolithiasis (kidney stones). Mechanistically, circPHAF1 is upregulated in kidney tissues during calcium oxalate stone formation, where it binds to general transcription factor IIF subunit 1 (GTF2F1) and recruits it to the C-C motif chemokine ligand 2 (CCL2) promoter, leading to sustained CCL2 activation and macrophage recruitment. Additionally, circPHAF1 is packaged into extracellular vesicles (EVs) and internalized by macrophages, promoting their polarization toward the inflammatory M1 phenotype. By targeting and degrading circPHAF1, these ASOs exert potent inhibitory effects on renal calcium oxalate crystal formation and associated inflammatory injury in vivo.
- Other names
- ASOs targeting circPHAF1antisense oligonucleotide targeting circPHAF1
Beyond the preview
Go deeper on antisense oligonucleotides targeting circPHAF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense oligonucleotides targeting circPHAF1.